Deoxyribonucleic acid (DNA) and DNA-handling enzymes (DNA)

DNA and DNA-handling enzymes constitute a broad and vital class of therapeutic targets essential for the storage, replication, and repair of genetic information. DNA itself can be targeted by small molecules that alkylate or intercalate into the double helix, thereby inducing structural damage that triggers apoptosis, a strategy widely used in chemotherapy (National Cancer Institute, 2023). DNA-handling enzymes, such as topoisomerases, polymerases, and helicases, facilitate the complex topological changes and synthesis required for cell division and gene expression (Nature Reviews Molecular Cell Biology, 2020). Pharmacological inhibition of these enzymes is a cornerstone of both anticancer and antimicrobial therapies. For instance, fluoroquinolones target bacterial DNA gyrase, while PARP inhibitors exploit synthetic lethality in cancers with DNA repair defects (PubMed, PMC7284581). Because these processes are fundamental to all living cells, drugs in this category often face challenges related to systemic toxicity and the potential for inducing new mutations (StatPearls, 2023). Current research focuses on increasing the specificity of these agents to minimize damage to healthy tissues while maximizing impact on rapidly dividing or repair-deficient cells (Journal of Clinical Oncology, 2022). This target class remains one of the most clinically validated areas in pharmacology, spanning oncology, infectious disease, and virology.

Other names

Deoxyribonucleic acidDNA replication machineryDNA repair enzymesReplisome componentsDNA-modifying agentsGenome maintenance machinery

Drugs targeting this group act through various mechanisms including direct DNA cross-linking, alkylation, intercalation between base pairs, inhibition of DNA strand break repair, and blocking the catalytic activity of enzymes like topoisomerases or polymerases to prevent replication and transcription (PubMed, PMC3544313; StatPearls, NBK538225).